George James is a Psychiatry physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3905 National Dr
Ste 250
Burtonsville, MD 208666104
Telephone
301-421-4233Registry record last updated 17 Jun 2018.
Clinical trials
- Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Sponsor: Insel Gruppe AG, University Hospital Bern
- Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Sponsor: Carelon Research
- Red Cell Storage Duration Study
Sponsor: Carelon Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alkermes, Inc.Program year20255 payments
- Lundbeck LLCProgram year20254 payments
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.9%Atypical Antipsychotic18.4%Quetiapine Fumarate25%Aripiprazole15%Vraylar12%Olanzapine11%Risperidone10%Clozapine5%Lurasidone Hcl5%Caplyta4%Invega Sustenna4%Rexulti4%Abilify Maintena4%Ziprasidone Hcl2%Part D<11 patientsSSRI16.5%Trazodone Hcl37%Sertraline Hcl22%Escitalopram Oxalate20%Fluoxetine Hcl19%Paroxetine Hcl3%Part D<11 patients+ 24 more classes in this area
Cardiovascular
2.1%alpha-Adrenergic Blocker2.1%Prazosin Hcl61%Doxazosin Mesylate40%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”